|
Candel Therapeutics, Inc. (CADL) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Candel Therapeutics, Inc. (CADL) Bundle
Gain insights into your Candel Therapeutics, Inc. (CADL) valuation analysis using our state-of-the-art DCF Calculator! This Excel template comes preloaded with real CADL data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Candel Therapeutics, Inc. (CADL).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .1 | .1 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | -100 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -8.2 | -13.7 | -25.5 | -17.3 | -37.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -6557.6 | -10975.2 | -20395.2 | -13853.6 | 100 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .0 | .1 | .2 | 1.0 | 1.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 34.4 | 72.8 | 185.6 | 789.6 | 100 | 81.44 | 81.44 | 81.44 | 81.44 | 81.44 |
| EBIT | -8.2 | -13.8 | -25.7 | -18.3 | -38.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -6592 | -11048 | -20580.8 | -14643.2 | 100 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 45.1 | 35.1 | 82.6 | 70.1 | 35.4 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 0 | 100 | 20 | 20 | 20 | 20 | 20 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 100 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | .2 | .9 | 1.6 | .4 | .4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 174.4 | 736.8 | 1272 | 304 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.2 | -1.5 | -1.8 | -1.3 | -.5 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -127.2 | -1180.8 | -1468 | -1037.6 | 100 | -80 | -80 | -80 | -80 | -80 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -8.0 | -17.3 | -25.8 | -2.8 | -38.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7.9 | -18.0 | -26.7 | -4.3 | -37.8 | -.4 | .0 | .0 | .0 | .0 |
| WACC, % | 5.31 | 5.32 | 5.32 | 5.01 | 5.32 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -13 | |||||||||
| Equity Value | 12 | |||||||||
| Diluted Shares Outstanding, MM | 29 | |||||||||
| Equity Value Per Share | 0.42 |
What You Will Get
- Real Candel Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Candel Therapeutics, Inc. (CADL).
- Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to evaluate the impact of changes on Candel Therapeutics’ fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections specific to Candel Therapeutics, Inc. (CADL).
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility in your financial assessments.
Key Features
- Comprehensive Clinical Data: Access detailed pre-loaded historical clinical trial results and future development projections for Candel Therapeutics, Inc. (CADL).
- Adjustable Research Parameters: Modify highlighted fields to tailor assumptions like discount rates, growth expectations, and operational margins.
- Real-Time Analytics: Instant updates to valuation models, Net Present Value (NPV), and revenue forecasts based on the latest data.
- Interactive Visualization Tools: User-friendly graphs and summaries to effectively communicate your investment analysis.
- Designed for All Experience Levels: An accessible layout suitable for investors, analysts, and healthcare consultants alike.
How It Works
- Step 1: Download the prebuilt Excel template featuring Candel Therapeutics' data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Candel Therapeutics' intrinsic value.
- Step 5: Make informed investment decisions or generate reports based on the outputs.
Why Choose This Calculator for Candel Therapeutics, Inc. (CADL)?
- Accurate Data: Real Candel Therapeutics financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to align with your projections.
- Time-Saving: Pre-built calculations streamline your analysis and save time.
- Professional-Grade Tool: Tailored for investors, analysts, and industry consultants.
- User-Friendly: Intuitive design and clear instructions make it accessible for all users.
Who Should Use Candel Therapeutics, Inc. (CADL)?
- Investors: Make informed decisions with insights from a leading biotech company focused on innovative therapies.
- Healthcare Analysts: Streamline your research with comprehensive data on cutting-edge therapeutic development.
- Consultants: Efficiently tailor presentations and reports using Candel's latest advancements and research findings.
- Biotech Enthusiasts: Enhance your knowledge of the biopharmaceutical landscape through Candel's pioneering approaches.
- Educators and Students: Utilize Candel’s developments as a case study in biotechnology and pharmaceutical courses.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Candel Therapeutics, Inc. (CADL) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Candel Therapeutics, Inc. (CADL).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.